NAV

Thymopentin

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Thymopentin
DrugBank Accession Number
DB11996
Background

Thymopentin has been used in trials studying the treatment and prevention of HIV Infections and Hepatocellular Carcinoma.

Type
Small Molecule
Groups
Investigational
Structure
Similar Structures
Weight
Average: 679.776
Monoisotopic: 679.365324194
Chemical Formula
C30H49N9O9
Synonyms
  • Thymopentin
  • Thymopentine
  • Thymopentinum
  • Timopentina
External IDs
  • ORF 15244
  • ORF-15244
  • TP-5
Poor quality drug data slowing you down?
Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.
Download eBook
Poor quality drug data slowing you down?
Download eBook

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now

Categories

ATC Codes
L03AX09 — Thymopentin
Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
O3Y80ZF13F
CAS number
69558-55-0
InChI Key
PSWFFKRAVBDQEG-XXTQFKTOSA-N
InChI
InChI=1S/C30H49N9O9/c1-16(2)24(28(46)38-22(29(47)48)14-17-8-10-18(40)11-9-17)39-27(45)21(15-23(41)42)37-26(44)20(7-3-4-12-31)36-25(43)19(32)6-5-13-35-30(33)34/h8-11,16,19-22,24,40H,3-7,12-15,31-32H2,1-2H3,(H,36,43)(H,37,44)(H,38,46)(H,39,45)(H,41,42)(H,47,48)(H4,33,34,35)/t19-,20-,21-,22-,24?/m0/s1
IUPAC Name
(3S)-3-[(2S)-6-amino-2-[(2S)-2-amino-5-[(diaminomethylidene)amino]pentanamido]hexanamido]-3-[(1-{[(1S)-1-carboxy-2-(4-hydroxyphenyl)ethyl]carbamoyl}-2-methylpropyl)carbamoyl]propanoic acid
SMILES
CC(C)C(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCCN=C(N)N)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O

References

General References
Not Available
PubChem Compound
451417
PubChem Substance
347828316
ChemSpider
26232604
RxNav
40230
ChEBI
135870
ChEMBL
CHEMBL156025
Wikipedia
Thymopentin

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections1
3Unknown StatusPreventionHepatocellular Carcinoma1
2CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections1
2Not Yet RecruitingTreatmentCarcinoma / Solid Tumors1
Not AvailableCompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections5

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Injection, solution
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0662 mg/mLALOGPS
logP-3.3ALOGPS
logP-6.3Chemaxon
logS-4ALOGPS
pKa (Strongest Acidic)3.2Chemaxon
pKa (Strongest Basic)11.29Chemaxon
Physiological Charge1Chemaxon
Hydrogen Acceptor Count14Chemaxon
Hydrogen Donor Count11Chemaxon
Polar Surface Area327.67 Å2Chemaxon
Rotatable Bond Count22Chemaxon
Refractivity171.76 m3·mol-1Chemaxon
Polarizability70.84 Å3Chemaxon
Number of Rings1Chemaxon
Bioavailability0Chemaxon
Rule of FiveNoChemaxon
Ghose FilterNoChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-001i-0121319000-1509269817c11ad9385a
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-02di-1404519000-c73793c665568332f3cf
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-00e9-3839405000-c80f73e9ef1854e767d2
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-014i-3907518000-287964b26431172dcc12
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-05fr-6479015000-0209a4b935e794736107
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-0a5c-7898111000-f5e4c043829c2e792d84
Chromatographic Properties
Collision Cross Sections (CCS)
Not Available

Drug created at October 20, 2016 21:09 / Updated at March 31, 2023 20:25